Our proprietary adjuvant technology platform is based on synthetic DNA sequences that activate the innate immune response by engaging TLR9. For vaccination, TLR9 agonists can be combined with vaccine antigens to increase the visibility of the antigen and stimulate an immune response to prevent infection. This combination induces a highly specific helper T cell response and is designed to generate memory T and B cells for long-term protection.